Chronic Fatigue syndrome Chronisch vermoeidheidssyndroom
Conditions
Interventions
[11C]PK11195 (a ligand for the TSPO protein, upregulated in activated microglia cells) is injected in both patients, and healthy age- and sexe-matched controls. Binding of this tracer will be visualis
Sponsors
University Medical Center Groningen
9713 GZ Groningen, The Netherlands
Eligibility
Inclusion criteria
Inclusion criteria: Control subjects: - Female, between 18 and 60 years old; - Healthy age- and sexe-matched controls, i.e. live in the same neighbourhood as the Chronic Fatigue Syndrome patient Chronic Fatigue Syndrome (CFS) patients: -Diagnosis according to the Dutch guideline on QFS [RIVM, Q-koortsvermoeidheidssyndroom]; - Female, between 18 and 60 years old; - Score of ¡Ý40 on the subscale fatigue severity of the CIS (Checklist Individual Strength); - Marked functional impairment assessed with the Sickness Impact Profile (SIP-8) and operationalised as a total score of ¡Ý700.
Exclusion criteria
Exclusion criteria: All subjects: - Women who are pregnant; - Women who intend to get pregnant during the study; - Use or having used psychotropic medication in the past six months; - Alcohol or substance abuse in the past 3 months; - Evident somatic/psychiatric co-morbidity; - Presence of materials in the body that can be magnetized and cannot be removed; - Participation in a scientific research study during the past year involving radiation. - Use or having used Doxycyclin in the past 6 months; CFS patients, additional -History of Q fever; -Vaccinated for Q fever. Healthy volunteers, additional -History of Q fever; -Vaccinated for Q fever
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective of this study is to evaluate whether there is an increased binding potential of the TSPO ligand [11C]PK11195, which is a marker for microglia activation in neuroinflammation, using PET in patients with chronic fatigue syndrome compared to Q-fever fatigue syndrome and healthy age- and sexe-matched controls. | — |
Secondary
| Measure | Time frame |
|---|---|
| - To correlate the binding potential of [11C]PK11195 to MRI measurements in the same patients (for example grey matter reduction). - To correlate binding potential of [11C]PK11195 to fatigue severity using the CIS fatigue questionnaire. - To correlate binding potential of [11C]PK11195 expression to peripheral cytokine concentrations. | — |
Contacts
Public ContactRuud Raijmakers
Department of Internal Medicine, route 463 Radboudumc
Outcome results
None listed